Cetera Advisor Networks’s Royalty Pharma RPRX Stock Holding History

Cetera Advisor Networks’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-15,882	Closed	-$431K	–	2855
2023 Q3	$431K	Buy	+15,882	New	+$472K	﹤0.01%	1876
2020 Q3	–	Sell	-2,605	Closed	-$126K	–	2661
2020 Q2	$126K	Buy	+2,605	New	+$129K	﹤0.01%	1375

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cetera Advisor Networks's RPRX Position: Q4 2023 in Review

Cetera Advisor Networks sold out of Royalty Pharma (RPRX) in Q4 2023, closing a stake of 15,882 shares — an estimated $431K sold.

Cetera Advisor Networks first reported a position in RPRX in Q2 2020 and held it in 2 quarters. The position peaked at $431K in Q3 2023. 363 funds tracked by Wall St. Rank hold RPRX as of Q4 2023.

Cetera Advisor Networks reported no remaining Royalty Pharma position as of Q4 2023 after selling out during the quarter.
Cetera Advisor Networks sold 15,882 Royalty Pharma shares in Q4 2023, an estimated $431K.
Cetera Advisor Networks first reported a position in Royalty Pharma in Q2 2020 and held it in 2 quarters.
Cetera Advisor Networks's Royalty Pharma position peaked at $431K in Q3 2023.
363 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2023.

Based on Cetera Advisor Networks's 13F filing for Q4 2023, filed 13 Feb 2024.